Routine

Thyroid nodule & multinodular goitre (incl. red-flag malignancy triage)

thyroid · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Thyroid nodules are very common; only ~5-10% are malignant. Goal is to triage: assess thyroid function, risk-stratify by ultrasound, and biopsy where indicated. Large goitres may cause compressive symptoms. Autonomous (toxic) nodules cause hyperthyroidism.

Red flags

  • Rapidly growing, hard, fixed nodule; hoarseness/vocal cord palsy; stridor or dysphagia
  • Cervical lymphadenopathy
  • Age <20 or >70, male, prior neck irradiation, family history of thyroid cancer/MEN2
  • Raised calcitonin
  • Retrosternal goitre with positive Pemberton sign (facial congestion on arm elevation)

Assessment

Differential diagnosis

  • Benign colloid nodule / cyst (commonest)
  • Differentiated thyroid cancer (papillary, follicular)
  • Medullary thyroid carcinoma (raised calcitonin; MEN2)
  • Anaplastic carcinoma / lymphoma (rapid, hard, fixed — urgent)
  • Toxic adenoma / toxic multinodular goitre
  • Parathyroid adenoma or thyroglossal/branchial lesion

Investigations

  • TSH first: if suppressed, get uptake scan (hot/autonomous nodule rarely malignant — treat as hyperthyroidism)
  • Thyroid ultrasound with risk score (U-classification / TIRADS) — size, solidity, calcification, margins, vascularity
  • Ultrasound-guided FNA cytology (Thy/Bethesda categories) for sonographically suspicious or large nodules
  • Calcitonin if medullary carcinoma suspected or before thyroid surgery [verify local practice]
  • CT/MRI neck + thorax if retrosternal extension or compressive symptoms (avoid iodinated contrast if planning RAI)
  • Flow-volume loop / nasendoscopy if airway or vocal cord concern

Management

  • Check TSH in every nodule — decides scan vs FNA pathway
  • Risk-stratify by ultrasound; biopsy per TIRADS/U-score and size thresholds
  • Red-flag features (see below) → urgent 2-week-wait cancer referral
  • Benign cytology + asymptomatic → ultrasound surveillance, discharge if stable
  • Compressive / retrosternal / cosmetic goitre → surgery (hemithyroidectomy or total)
  • Autonomous toxic nodule → radioiodine or surgery; antithyroid drug as bridge
  • Multidisciplinary (MDT) discussion for indeterminate or malignant cytology

Drugs & doses

Levothyroxine suppression therapy is NOT recommended for benign nodules (ineffective, harmful) [per guidelines]
For toxic nodule bridging: carbimazole 20-40 mg PO od + propranolol 20-40 mg 8-hourly (see hyperthyroidism entry)
Levothyroxine replacement post-total thyroidectomy 1.6 µg/kg/day (suppressive dose if proven cancer, per oncology)

Disposition

Outpatient endocrine/ENT clinic. Urgent 2-week cancer pathway for red flags. Admit only for acute airway compromise.

Complications & pitfalls

  • Airway compromise from large/retrosternal goitre
  • Missed malignancy
  • Post-surgical: recurrent laryngeal nerve palsy, hypoparathyroidism/hypocalcaemia
  • Thyrotoxicosis from autonomous nodule

Exam pearls

  • TSH first — a suppressed TSH points to an autonomous 'hot' nodule that almost never needs biopsy.
  • Most incidental nodules found on CT/carotid Doppler are benign; avoid over-investigation of small, low-risk nodules.
  • FNA cytology (Bethesda/Thy system) guides management; molecular testing refines indeterminate results in some centres.
  • Avoid iodinated CT contrast if radioiodine scan/treatment is planned.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.